OBJECTIVE：To observe the efficacy and safety of Shenmai injection combined with gemcitabine and cisplatin in the treatment of lung adenocarcinoma and its effects on changes of CT net added value. METHODS：86 patients with III B and IV lung adenocarcinoma were randomly divided into control group and observation group. Control group was treated with 1 000-1 250 mg/m2 Gemcitabine hydrochloride for injection，adding into 250 ml 0.9％ Sodium chloride injection by intravenous infusion， d1，8， once a day+25 mg/m2 Cisplatin injection，adding in to 250 ml 0.9％ Sodium chloride injection by intravenous infusion， once a day， d1-3. Observation group was additionally treated with 50 ml Shenmai injection， adding into 250 ml 5％ Glucose injection by intravenous infusion， once a day， for continuous 21 d. 21 d was regarded as 1 course， and the efficacy was evaluated after 3 courses. T lymphocyte populations （CD3+，CD4+，CD8+，CD4+/CD8+）， Piper fatigue self-assessment scale （PFS） score， cancer quality of life assessment questionnaires （QLQ-30） score， CT net added value and toxicity before and after treatment reactions in 2 groups were observed. RESULTS：The total effective rate in observation group was significantly higher than control group， the incidences of leukopenia， thrombocytopenia and gastrointestinal reactions were significantly lower than control group， the differences were statistically significant（P＜0.05）. There was no significant difference in the T lymphocyte populations in observation group before and after treatment（P＞0.05）， T lymphocyte populations in control group were significantly lower than before and observation group， the differences were statistically significant（P＜0.05）； PFS score and CT net added value in 2 groups were significantly lower than before， and observation group was lower than control group， QLQ-30 score was significantly higher than before， and observation group was higher than control group， the differences were statistically significant（P＜0.05）. And there was no significant difference in the incidence of adverse reactions（P＞0.05）. CONCLUSIONS： The efficacy of Shenmai injection combined with gemcitabine and cisplatin regimen in the treatment of lung adenocarcinoma is obvious， it can improve the immunity， reduce the sense of fatigue and decrease CT net added value， with good safety.